A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors.

Autor: Janku, Filip1 (AUTHOR) fjanku@monterosatx.com, Choong, Grace M.2 (AUTHOR) choong.grace@mayo.edu, Opyrchal, Mateusz3 (AUTHOR) mopyrch@iu.edu, Dowlati, Afshin4 (AUTHOR) afshin.dowlati@uhhospitals.org, Hierro, Cinta5 (AUTHOR) chierro@iconcologia.net, Rodon, Jordi1,5 (AUTHOR) jrodon@mdanderson.org, Wicki, Andreas6 (AUTHOR) andreas.wicki@usz.ch, Forster, Martin D.7 (AUTHOR) martin.forster@uclh.nhs.uk, Blagden, Sarah P.8 (AUTHOR) sarah.blagden@oncology.ox.ac.uk, Yin, Jun9 (AUTHOR) vivien.yin@moffitt.org, Reid, Joel M.2 (AUTHOR) reid@mayo.edu, Muller, Helene10 (AUTHOR) helene.muller@swissrockets.com, Cmiljanovic, Natasa10 (AUTHOR) natasa.cmiljanovic@swissrockets.com, Cmiljanovic, Vladimir10 (AUTHOR) vladimir.cmiljanovic@swissrockets.com, Adjei, Alex A.2 (AUTHOR) adjeia2@ccf.org
Zdroj: Cancers. Mar2024, Vol. 16 Issue 6, p1137. 17p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje